REFERENCES
- Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4: 1625–30.
- Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKemion JB, et al. In vitro modulation of tumour progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996; 77: 1862–72.
- Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160: 214–219.
- Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39–44.
- Correale P. Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89: 293–300.
- Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumour-specific CD8+ cyto-toxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36: 129–38.
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52.